title: Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus.
abstract: BACKGROUND
  To investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on plasma fibroblast growth factor-21 (FGF-21) levels in patients with newly diagnosed type 2 diabetes mellitus (nT2DM).
  
  
  METHODS
  Sixty-eight patients with nT2DM (nT2DM group), and 52 gender-, age- and body mass index (BMI) -matched normal glucose tolerance (NGT group) controls participated in the study. 30 nT2DM patients with FBG ≥ 14.0 mmol/L were treated with CSII for 2 weeks, and were underwent a euglycemic-hyperinsulinemic clamp pre- and post-treatment. Plasma FGF-21 concentrations were measured with a commercial ELISA kit. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed.
  
  
  RESULTS
  Fasting plasma FGF-21 levels were higher in the nT2DM group than in NGT groups (1.60 ± 0.08 vs. 1.13 ± 0.26 µg/L, P<0.01). In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after CSII treatment for 2 weeks (1.60 ± 0.08 vs.1.30 ± 0.05 µg/L, P<0.05), accompanied by a significant increase in the whole body glucose uptake (M value) and blood glucose control. The changes in plasma FGF-21 levels (ΔFGF-21) were positively associated with the amelioration of insulin resistance shown by the changes in M value.
  
  
  CONCLUSIONS
  Plasma FGF-21 level is associated with whole body insulin sensitivity and significantly reduced following short-term CSII treatment.
authors: Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
authors: Mengliu
authors: M
authors: Yang
authors: Jing
authors: J
authors: Dong
authors: Hua
authors: H
authors: Liu
authors: Ling
authors: L
authors: Li
authors: Gangyi
authors: G
authors: Yang
mesh_terms: D001786:Blood Glucose; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005215:Fasting / Q000097:blood; D005346:Fibroblast Growth Factors / Q000097:blood / Q000187:drug effects*; D005951:Glucose Tolerance Test; D006801:Humans; D055104:Infusions, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000494:pharmacology*; D007333:Insulin Resistance
chemical_list: D001786:Blood Glucose; D007328:Insulin; C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors